-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis (Alvotech SA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis (Alvotech SA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details:...
-
Product Insights
Choroidal Neovascularization – Drugs In Development, 2023
Global Markets Direct’s, ‘Choroidal Neovascularization - Drugs In Development, 2023’, provides an overview of the Choroidal Neovascularization pipeline landscape. The report provides comprehensive information on the therapeutics under development for Choroidal Neovascularization, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Post Menopausal Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegenzileukin in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegenzileukin in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegenzileukin in Colon Cancer Drug Details: SAR-444245 (THOR-707) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Denosumab Biosimilar in Autoimmune Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Autoimmune Disorders Drug Details: AVT-03 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Golimumab Biosimilar in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Golimumab Biosimilar in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Golimumab Biosimilar in Inflammation Drug Details:Monoclonal antibody is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Febuxostat + Inosine) in Mitochondrial Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Febuxostat + Inosine) in Mitochondrial Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Febuxostat + Inosine) in Mitochondrial DiseasesDrug Details:A fixed dose combination of...